
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics is positioned favorably due to its innovative approach in developing therapeutics that stimulate the immune system for cancer treatment, utilizing its proprietary PREDATOR platform to create conditionally activated molecules. The company's ability to selectively activate INDUKINE molecules in the tumor microenvironment is pivotal, potentially overcoming limitations inherent in conventional immune therapies. This strategic focus on advanced immunotherapy not only aligns with current market trends toward personalized medicine but also highlights Werewolf's potential for significant growth in a competitive biopharmaceutical landscape.
Bears say
Werewolf Therapeutics Inc. faces a challenging financial environment as indicated by the downward revision of full-year same-store revenue growth, which has been adjusted from a range of (0.35%)-1.15% to a new range of (0.20%)-0.40%. Additionally, the company reported a 30 basis points year-over-year decline in revenues alongside a 3.8% increase in expenses, leading to a 2.6% decrease in net operating income (NOI). Compounding these issues, the average effective rental rate has decreased by 50 basis points year-over-year, highlighting difficulties in maintaining revenue streams from new leases.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares